Proteome Sciences PLC Expansion into the US (1789Z)
12 May 2023 - 4:00PM
UK Regulatory
TIDMPRM
RNS Number : 1789Z
Proteome Sciences PLC
12 May 2023
12 May 2023
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Proteome Sciences expands into the US: New Facility to open in
San Diego
Proteome Sciences plc is pleased to announce the expansion of
its proteomics services into the United States of America ("US"). A
state of the art facility will be based in San Diego, California,
to provide easy access to the established and growing
pharmaceutical and biotechnology proteomics services requirements
across the US and, in particular, the research hubs on the west
coast. The Company's subsidiary, Proteome Sciences US Inc, has
commenced staff recruitment and the new facility is expected to be
fully operational in the fourth quarter of 2023.
Commenting on the new laboratory, Dr. Ian Pike, Chief Scientific
Officer and President of Proteome Sciences US Inc. said "This is a
major development for Proteome Sciences, building on the strong
foundations of our services business in Europe. Whilst we already
have an excellent customer base in the US, concerns over shipping
costs, timing delays and customs delays have restricted the volume
of orders that could be processed. We will now be able to provide a
more accessible service to the rapidly growing pharma/biotech
community across the US as the demand for proteomics services
continues to expand."
Dr. Mariola Söhngen, Chief Executive Officer of Proteome
Sciences plc, added "Internationalisation is a key element of our
growth strategy. With a major part of our service and reagent
business already focused over there, it is a logical step to
establish our own facility for customers in the US. This is a real
milestone for Proteome Sciences and we are looking forward to
improving our service to the US marketplace with the San Diego
facility opening later this year. "
For further information:
Proteome Sciences plc
Dr. Mariola Soehngen, Chief Executive Officer Tel: +44 (0)20 7043 2116
Dr. Ian Pike, Chief Scientific Officer
Richard Dennis, Chief Commercial Officer
Abdelghani Omari, Chief Financial Officer
Allenby Capital Limited (Nominated Adviser & Broker)
John Depasquale / Jeremy Porter (Corporate Finance) Tel: +44 (0) 20 3328 5656
Tony Quirke / Stefano Aquilino (Equity Sales & Corporate Broking)
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R)MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGPUPWAUPWPUG
(END) Dow Jones Newswires
May 12, 2023 02:00 ET (06:00 GMT)
Proteome Sciences (AQSE:PRM.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Proteome Sciences (AQSE:PRM.GB)
Historical Stock Chart
From Dec 2023 to Dec 2024